A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

• Status: Completed
• Trial end date: 2015-10-19
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bausch & Lomb Incorporated
• Treatments: Loteprednol Etabonate; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Subjects who have been treated with the study drug at least once and completed safety follow-up.

• Subjects who have been treated with the study drug at least once and completed the clinical efficacy assessment.

Exclusion Criteria:

• Subjects not treated with study drug at least once.